7-methoxy-11-[(2-carboxy)ethyl]-10-phenyldibenzo[b,f]thiepin | 267408-97-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并硫平类
• 英文名称: 7-methoxy-11-[(2-carboxy)ethyl]-10-phenyldibenzo[b,f]thiepin
• 英文别名: 3-(2-Methoxy-5-phenylbenzo[b][1]benzothiepin-6-yl)propanoic acid
• CAS: 267408-97-9
• 化学式: C₂₄H₂₀O₃S
• 分子量: 388.487
• InChiKey: KBXQPHJYHVUSPH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• USE OF TRIPHENYLBUTENE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
  申请人：AstraZeneca AB

  公开号：EP1127045A2

  公开（公告）日：2001-08-29
• TRIPHENYLBUTENE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
  申请人：AstraZeneca AB

  公开号：EP1127045B1

  公开（公告）日：2006-11-02
• US6489481B1
  申请人：——

  公开号：US6489481B1

  公开（公告）日：2002-12-03
• [EN] NEUROLOGICAL DISORDERS<br/>[FR] TROUBLES NEUROLOGIQUES
  申请人：ZENECA LTD

  公开号：WO2000025767A2

  公开（公告）日：2000-05-11

  The use of a compound of Formula (VIII) in the manufacture of a medicament for the treatment of or the prevention of neurological disorders, in a warm-blooded mammal, wherein A and B are selected from: Formula (IX) or Formula (X) such that when A is of Formula (X) then B is of Formula (IX) and when A is of Formula (IX) then B is of Formula (X). R1 is selected from hydrogen, halo, aryl, carbamoyl, N-C1-4alkylcarbamoyl or NN-di-C1-4alkylcarbamoyl; D is selected from C1-4alkylene, C1-4alkenylene or alkynylene; R2 is selected from hydrogen, C1-4alkyl or hydroxy; R3 is selected from hydrogen, hydroxy, halo, PO4, C1-4alkoxy, or a group of the formula: -E-F-G-H wherein: E is selected from: (a), (b), (c), (d), (e), or (f); F is selected from: (a), (b), or a direct bond; G is selected from C1-6alkyl, or a direct bond; H is selected from hydrogen, C1-4alkoxy, or optionally substituted aryl; heteroaryl, or carbocyclyl; R4 and R5 are independently selected from methyl, ethyl or phenyl, or together with the nitrogen atom to which they are attached form a ring selected from pyrrolidine, piperidine or morpholine; R6 is selected from hydrogen, C1-4alkyl; C1-4alkoxy, halo, or a ring fused phenyl group fused via carbons 3 and 4 on the phenyl group of Formula (X); R7 and R8 are either both hydrogen or when A is of Formula (X) may be joined either via a sulphur atom, via -CH2- or via -C2H4; R9 is selected from hydrogen or C1-4alkyl; and n is 2 or 3; or a pharmaceutically acceptable salt, prodrug or solvate thereof. Processes for their preparation of compounds of Formula (VIII) are described, as are compositions containing them and their use.